It is potential for N-of-1 trials to evaluate economics of health care, however, it is still in the exploratory stage. With the advantage of accurate estimation of costs and effects, it is beneficial to promote the application of N-of-1 trials for economic evaluation in the era of precision medicine. In this study, we introduce the necessity, feasibility, selection, calculation of indicators and influence factors of N-of-1 trials for economic evaluation, and in order to provide references for researchers to perform related studies.
Citation：
ZHAI Jingbo, LI Jiang, SHANG Hongcai, WANG Hui, DAI Min, CHEN Jing. An introduction of economic evaluation of N-of-1 trials. Chinese Journal of Evidence-Based Medicine, 2017, 17(6): 742-744. doi: 10.7507/1672-2531.201701078
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
王蕊, 刘宝. 关于精准医疗经济学评价的思考. 中国药房, 2016, 27(2): 149-153.
|
| 2. |
Nikles J, Mitchell G. The essential guide to N-of-1 trials in health. Germany: Springer Netherlands, 2015: 155-174.
|
| 3. |
Karnon J, Qizilbash N. Economic evaluation alongside n-of-1 trials: getting closer to the margin. Health Econ, 2001, 10(1): 79-82.
|
| 4. |
Scuffham PA, Nikles J, Mitchell GK, et al. Using N-of-1 trials to improve patient management and save costs. J Gen Intern Med, 2010, 25(9): 906-913.
|
| 5. |
徐婷婷, 方海. 卫生经济学评价指南介绍. 中国卫生经济, 2016, 35(5): 5-8.
|
| 6. |
于俊叶. 患者住院期间直接费用与间接费用的调查研究. 石家庄: 河北医科大学, 2008: 49-54.
|
| 7. |
黄碧瑜, 杨敏, 刘晓琦, 等. 肾病综合症患者预防血栓形成华法林和依诺肝素不同重叠用药方案选择的成本-效果分析. 中国循证医学杂志, 2016, 16(7): 754-759.
|
| 8. |
宗欣, 孙利华. 药物经济学评价方法及其评价标准. 中国药物经济学, 2011, (3): 79-85.
|
| 9. |
Scuffham PA, Yelland MJ, Nikles J, et al. Are N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian Experience. Value Health, 2008, 11(1): 97-109.
|
| 10. |
Pope JE, Prashker M, Anderson J. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. J Rheumatol, 2004, 31(1): 140-149.
|
- 1. 王蕊, 刘宝. 关于精准医疗经济学评价的思考. 中国药房, 2016, 27(2): 149-153.
- 2. Nikles J, Mitchell G. The essential guide to N-of-1 trials in health. Germany: Springer Netherlands, 2015: 155-174.
- 3. Karnon J, Qizilbash N. Economic evaluation alongside n-of-1 trials: getting closer to the margin. Health Econ, 2001, 10(1): 79-82.
- 4. Scuffham PA, Nikles J, Mitchell GK, et al. Using N-of-1 trials to improve patient management and save costs. J Gen Intern Med, 2010, 25(9): 906-913.
- 5. 徐婷婷, 方海. 卫生经济学评价指南介绍. 中国卫生经济, 2016, 35(5): 5-8.
- 6. 于俊叶. 患者住院期间直接费用与间接费用的调查研究. 石家庄: 河北医科大学, 2008: 49-54.
- 7. 黄碧瑜, 杨敏, 刘晓琦, 等. 肾病综合症患者预防血栓形成华法林和依诺肝素不同重叠用药方案选择的成本-效果分析. 中国循证医学杂志, 2016, 16(7): 754-759.
- 8. 宗欣, 孙利华. 药物经济学评价方法及其评价标准. 中国药物经济学, 2011, (3): 79-85.
- 9. Scuffham PA, Yelland MJ, Nikles J, et al. Are N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian Experience. Value Health, 2008, 11(1): 97-109.
- 10. Pope JE, Prashker M, Anderson J. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. J Rheumatol, 2004, 31(1): 140-149.
